Study of Treatment Used for Migraine Headaches (MK-0974-076)

• Status: Terminated
• Trial end date: 2012-03-23
• Target enrollment: 0
• Participant gender: All

Summary

This study will describe the reasons for triptan utilization patterns (continuation and discontinuation) in triptan-naïve participants and assess the stability of treatment utilization patterns over time according to standard medical guidelines or clinical practice standards of the investigating physician.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.

Criteria

Inclusion criteria:

• At least 18 years of age in the United States at the time of consent

• Physician-diagnosed migraine with or without aura

• At least two and up to a maximum of 8 moderate to severe migraine attacks during the 30 days prior to screening

• Initial triptan prescription 3 months (± 2 weeks) prior to being identified as eligible for this study, and triptan-naïve before that initial prescription

• Used triptan medication at least once within 6 months prior to the date of informed consent for screening

• Internet access and able to complete online surveys via electronic data entry

Exclusion criteria:

• Treated with triptans prior to this study

• In active litigation and compensation issues including disability dispute cases with a Government agency

• Participation in a clinical trial within the last 90 days